RNA injection aims to control blood sugar in type 2 diabetes

NCT ID NCT07347080

First seen Jan 21, 2026 · Last updated May 16, 2026 · Updated 15 times

Summary

This early-stage study tests a single injection of a new RNA-based medicine (CR059) in 9 Chinese adults with type 2 diabetes. The goal is to see if it is safe and how it affects blood sugar control. Participants must have been diagnosed within the last 5 years and have not responded well to diet, exercise, or metformin alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Henan University of Science and Technology

    RECRUITING

    Luoyang, Henan, 310015, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.